Shuaijun Li, Caiting Meng, Qian Hao, Ruina Zhou, Luyao Dai, Yucheng Guo, Sitong Zhao, Xin Zhou, Chunju Lou, Ji Xu, Peng Xu, Jinfan Yang, Yifan Ding, Yanni Lv, Shengli Han, Shuai Li, Jing Li, Huafeng Kang, Zhengtao Xiao, Mingqian Tan, Xiaobin Ma, Hao Wu
Non-small cell lung cancer (NSCLC) brain metastases present a significant treatment challenge due to limited drug delivery efficiency and severe adverse reactions. In this study, we address these challenges by designing a "on/off" switchable crosslinked paclitaxel (PTX) nanocarrier, BPM-PD, with novel ultra-pH-sensitive linkages (pH 6.8 to 6.5). BPM-PD demonstrates a distinct "on/off" switchable release of the anti-cancer drug paclitaxel (PTX) in response to the acidic extratumoral microenvironment. The "off" state of BPM-PD@PTX effectively prevents premature drug release in the blood circulation, blood-brain barrier (BBB)/blood-tumor barrier (BTB), and normal brain tissue, surpassing the clinical PTX-nanoformulation (nab-PTX)...
March 14, 2024: Biomaterials